Eduardo Zubizarreta

Eduardo Zubizarreta

Auto-generated profile, based on publicly available information

Eduardo Zubizarreta

Division of Human Health, International Atomic Energy Agency, Vienna, Austria

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
MAMay Abdel-Wahab
May Abdel-Wahab
SGSoehartati Gondhowiardjo
Soehartati Gondhowiardjo
ARArthur Accioly Rosa
Arthur Accioly Rosa
YLYolande Lievens
Yolande Lievens
NENoura El-Haj
Noura El-Haj
MGMary Gospodarowicz
Mary Gospodarowicz
Recognizing the increase in cancer incidence globally and the need for effective cancer control interventions, several organizations, professional bodies, and international institutions have proposed strategies to improve treatment options and reduce mortality along with minimizing overall incidence. Despite these efforts, an estimated 9.6 million deaths in 2018 was attributed to this noncommunicable disease, making it the second leading cause of death worldwide. Left unchecked, this will further increase in scale, with an estimated 29.5 million new cases and 16.3 million deaths occurring worldwide in 2040. Although it is known and generally accepted that cancer services must include radiotherapy, such access is still very limited in many parts of the world, especially in low- and middle-income countries. After thorough review of the current status of radiotherapy including programs worldwide, as well as achievements and challenges at the global level, the International Atomic Energy Agency convened an international group of experts representing various radiation oncology societies to take a closer look into the current status of radiotherapy and provide a road map for future directions in this field. It was concluded that the plethora of global and regional initiatives would benefit further from the existence of a central framework, including an easily accessible repository through which better coordination can be done. Supporting this framework, a practical inventory of competencies needs to be made available on a global level emphasizing the knowledge, skills, and behavior required for a safe, sustainable, and professional practice for various settings. This white paper presents the current status of global radiotherapy and future directions for the community. It forms the basis for an action plan to be developed with professional societies worldwide.

1 April 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DRDanielle Rodin
Danielle Rodin
BTBouchra Tawk
Bouchra Tawk
OMOsama Mohamad
Osama Mohamad
SGSurbhi Grover
Surbhi Grover
Fabio Ynoe de MoraesFabio Ynoe de Moraes
Fabio Ynoe de Moraes
YLYolande Lievens
Yolande Lievens

1 December 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JCJessica Chan
Jessica Chan
APAlfredo Polo
Alfredo Polo
EZEduardo Zubizarreta
Eduardo Zubizarreta
JBJean Marc Bourque
Jean Marc Bourque
THTimothy Hanna
Timothy Hanna
MAMay Abdel-Wahab
May Abdel-Wahab

23 October 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AJAlexandre Arthur Jacinto
Alexandre Arthur Jacinto
EFEronides Salustiano Batalha Filho
Eronides Salustiano Batalha Filho
LVLuciano de Souza Viana
Luciano de Souza Viana
PMPedro De Marchi
Pedro De Marchi
RCRenato de Castro Capuzzo
Renato de Castro Capuzzo
ACAndre Lopes Carvalho
Andre Lopes Carvalho
The evolution of radiotherapy over recent decades has reintroduced the hypofractionation for many tumor sites with similar outcomes to those of conventional fractionated radiotherapy. The use of hypofractionation in locally advanced head and neck cancer (LAHNC) has been already used, however, its use has been restricted to only a few countries. The aim of this trial was to evaluate the safety and feasibility of moderate hypofractionated radiotherapy (HYP-RT) with concomitant cisplatin (CDDP). This single-arm trial was designed to evaluate the safety and feasibility of HYP-RT with concomitant CDDP in LAHNC. Stage III and IV patients withnonmetastatic disease were enrolled. Patients were submitted to intensity modulatedradiation therapy, which comprised 55 Gy/20 fractions to the gross tumor and44–48 Gy/20 fractions to the areas of subclinical disease. Concomitant CDDPconsisted of 4 weekly cycles of 35 mg/m2. The primary endpoints were the treatment completion rate and acute toxicity. Twenty patients were enrolled from January 2015 to September 2016, and 12 (60%) were classified as unresectable. All patients completed the total dose of radiotherapy, and 19 patients (95%) received at least 3 of 4 cycles of chemotherapy. The median overall treatment time was 29 days (27–34). Grade 4 toxicity was reported twice (1 fatigue and 1 lymphopenia). The rates of grade 3 dermatitis and mucositis were 30% and 40%, respectively, with spontaneous resolution. Nasogastric tubes were offered to 15 patients (75%) during treatment; 4 patients (20%) needed feeding tubes after 2 months, and only 1 patient needed a feeding tube after 12 months. HYP-RT with concomitant CDDP was considered feasible for LAHNC, and the rate of acute toxicity was comparable to that of standard concomitant chemoradiation. A feeding tube was necessary for most patients during treatment. Further investigation of this strategy is warranted. ClinicalTrials, NCT03194061 . Registered 21 Jun 2017 – Retrospectively registered.

16 December 2020 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
VVVolodymyr Vinnikov
Volodymyr Vinnikov
PHPrakash Hande
Prakash Hande
RWRuth Wilkins
Ruth Wilkins
AWAndrzej Wojcik
Andrzej Wojcik
EZEduardo Zubizarreta
Eduardo Zubizarreta
OBOleg Belyakov
Oleg Belyakov
A search for effective methods for the assessment of patients’ individual response to radiation is one of the important tasks of clinical radiobiology. This review summarizes available data on the use of ex vivo cytogenetic markers, typically used for biodosimetry, for the prediction of individual clinical radiosensitivity (normal tissue toxicity, NTT) in cells of cancer patients undergoing therapeutic irradiation. In approximately 50% of the relevant reports, selected for the analysis in peer-reviewed international journals, the average ex vivo induced yield of these biodosimetric markers was higher in patients with severe reactions than in patients with a lower grade of NTT. Also, a significant correlation was sometimes found between the biodosimetric marker yield and the severity of acute or late NTT reactions at an individual level, but this observation was not unequivocally proven. A similar controversy of published results was found regarding the attempts to apply G2- and γH2AX foci assays for NTT prediction. A correlation between ex vivo cytogenetic biomarker yields and NTT occurred most frequently when chromosome aberrations (not micronuclei) were measured in lymphocytes (not fibroblasts) irradiated to relatively high doses (4–6 Gy, not 2 Gy) in patients with various grades of late (not early) radiotherapy (RT) morbidity. The limitations of existing approaches are discussed, and recommendations on the improvement of the ex vivo cytogenetic testing for NTT prediction are provided. However, the efficiency of these methods still needs to be validated in properly organized clinical trials involving large and verified patient cohorts.

4 February 2011 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
ESEeva K Salminen
Eeva K Salminen
KKKrystyna Kiel
Krystyna Kiel
GIGeoffrey S Ibbott
Geoffrey S Ibbott
MJMichael C Joiner
Michael C Joiner
EREduardo Rosenblatt
Eduardo Rosenblatt
AMAhmed Meghzifene
Ahmed Meghzifene
The IAEA held the International Conference on Advances in Radiation Oncology (ICARO) in Vienna on 27-29 April 2009. The Conference dealt with the issues and requirements posed by the transition from conventional radiotherapy to advanced modern technologies, including staffing, training, treatment planning and delivery, quality assurance (QA) and the optimal use of available resources. The current role of advanced technologies (defined as 3-dimensional and/or image guided treatment with photons or particles) in current clinical practice and future scenarios were discussed.